Investing Profile

Michal Silverberg

VC
Managing Director at Novartis Venture Fund -NVF
Photo of Michal Silverberg, Managing Director at Novartis Venture Fund

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Hotmail Network
4901 CONNECTIONS
Hotmail Network
4901 CONNECTIONS
Columbia University in the City of New York Network
259 CONNECTIONS
Columbia University Network
148 CONNECTIONS
University of Haifa Network
13 CONNECTIONS
cb
Novartis Venture Fund Managing Director
$5.0M - $10.0M
$7.5M
5
$750M
CompanyStageDateRound SizeTotal Raised
Sidewinder Therapeutics
Series BApr 2026$140M
$140M
Co-investors: John Hamer (DCVC (Data Collective)), Daniel Estes (Frazier Healthcare Partners)
Fore Biotherapeutics
Series DMay 2025$40M
Series DAug 2023$75M
$180M
Co-investors: Roberto De Ponti (3B Future Health Ventures (Helsinn Investment Fund)), Simeon J. George (SR One), Ran Nussbaum (Pontifax Venture Capital), Chandra Leo (HBM Partners AG), Matthew Foy (SROne)
Twentyeight-Seven Therapeutics
Series AMay 2019$15M
Series ASep 2018$65M
$80M
Co-investors: Kazumi Shiosaki (MPM Capital), Henrijette Richter (Sofinnova Partners)
VP Business Development and Operation MultiGene Vascular Systems (MGVS) LtdPresent
Manager Business Development HotmailPresent
Senior Director Business Development and New Product Commercialization Novo NordiskPresent
Managing Director HotmailPresent
Senior Partner Takeda Ventures, Inc.Present
University of Haifa BA Economics & Business
Columbia University MA Biotechnology
Columbia University in the City of New York MA Biotechnology